Figure 5 | Scientific Reports

Figure 5

From: Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

Figure 5The alternative text for this image may have been generated using AI.

Comparison of baseline cytokine levels among HCV-non-infected patients with previous HBV infection with or without HBV reactivation during anti-cancer/immunosuppressive therapy or bone marrow transplantation. Each data are shown as median ± SD. *P < 0.05, **P < 0.01. HCV hepatitis C virus, HBV hepatitis B virus, IL interleukin, MCP monocyte chemotactic protein, IFN interferon, TNF tumor necrosis factor, SD standard deviation, R HBV reactivation, N-R non-HBV reactivation, prHBV previously resolved HBV infection.

Back to article page